AURKA and head and neck squamous cell carcinoma: The combination of alisertib and pembrolizumab showed acceptable tolerability and disease stabilization in immunotherapy-resistant patients, whereas AURKA inhibition decreased resistance in retinoblastoma protein-deficient head and neck squamous cell carcinoma [26].